Key result
Andexanet alfa effectively reverses the anticoagulant effects of factor Xa inhibitors, though it carries a boxed warning for thromboembolic and ischemic risks occurring in up to 18% of patients.
Population
Patients receiving direct oral anticoagulants who require reversal due to severe or life-threatening bleeding
Design
Review
Authors
Loading...
May support andexanet alfa for urgent DOAC reversal; leaves open optimal risk-benefit assessment in practice.
Andexanet alfa represents a therapeutic advance for reversing DOAC-associated severe or life-threatening bleeding, despite boxed warnings for thromboembolic and ischemic risks.
Sible et al. (2018) conducted a review in DOAC-associated severe or life-threatening bleeding. Andexanet alfa was evaluated. Andexanet alfa effectively reverses the anticoagulant effects of factor Xa inhibitors, though it carries a boxed warning for thromboembolic and ischemic risks occurring in up to 18% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: